Determination of rivaroxaban in human plasma samples
<p>Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring. Nearly 60% of rivaroxaban is cleared from circulation b...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17. Februar 2012
|
| In: |
Seminars in thrombosis and hemostasis
Year: 2012, Jahrgang: 38, Heft: 2, Pages: 178-184 |
| ISSN: | 1098-9064 |
| DOI: | 10.1055/s-0032-1301415 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1055/s-0032-1301415 Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1301415 
|
| Verfasserangaben: | Job Harenberg, Sandra Erdle, Svetlana Marx, Roland Krämer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 157841816X | ||
| 003 | DE-627 | ||
| 005 | 20230913100817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0032-1301415 |2 doi | |
| 035 | |a (DE-627)157841816X | ||
| 035 | |a (DE-576)50841816X | ||
| 035 | |a (DE-599)BSZ50841816X | ||
| 035 | |a (OCoLC)1341016441 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 245 | 1 | 0 | |a Determination of rivaroxaban in human plasma samples |c Job Harenberg, Sandra Erdle, Svetlana Marx, Roland Krämer |
| 264 | 1 | |c 17. Februar 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.08.2018 | ||
| 520 | |a <p>Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring. Nearly 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug. Therefore, as renal elimination plays a pivotal role in the metabolism of this drug, impairment of renal function may be important during anticoagulation with rivaroxaban over long periods of time. The assessment of the anticoagulant effect/concentration of rivaroxaban may thus be useful in special patient populations such as in the elderly and eldest, during acute diseases with concurrent dehydration, before surgery, during bleeding or thrombotic episodes, or to verify adherence to therapy. Rivaroxaban prolongs prothrombin time in a dose-dependent, linear fashion. Activated partial thromboplastin time (APTT) is also prolonged, but in an exponential manner. Substantial differences in test results might be generated by different thromboplastin and APTT reagents. One-step prothrombin-induced clotting time assay is sensitive to low concentrations of rivaroxaban. Chromogenic substrate assays specific for factor Xa are also sensitive to rivaroxaban. Several initiatives are currently ongoing to standardize the various methods to determine rivaroxaban in human plasma samples, some of which will be summarized in this article along with the dose-dependent effects of rivaroxaban on relevant coagulation parameters. Therefore, although rivaroxaban prolongs all coagulation assays used to assess the anticoagulant effects of most anticoagulants, the most specific assay cannot be identified at present. Moreover, clinical trials are needed to determine the relationship of assay results with bleeding or thrombotic complications.</p> | ||
| 700 | 1 | |a Erdle, Sandra |d 1989- |e VerfasserIn |0 (DE-588)1048606996 |0 (DE-627)780716493 |0 (DE-576)402454499 |4 aut | |
| 700 | 1 | |a Hetjens, Svetlana |d 1983- |e VerfasserIn |0 (DE-588)1031801979 |0 (DE-627)737600284 |0 (DE-576)379534223 |4 aut | |
| 700 | 1 | |a Krämer, Roland |e VerfasserIn |0 (DE-588)1020469730 |0 (DE-627)691227861 |0 (DE-576)360500331 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in thrombosis and hemostasis |d New York, NY : Thieme, 1974 |g 38(2012), 2, Seite 178-184 |h Online-Ressource |w (DE-627)342892754 |w (DE-600)2072469-X |w (DE-576)279447868 |x 1098-9064 |7 nnas |a Determination of rivaroxaban in human plasma samples |
| 773 | 1 | 8 | |g volume:38 |g year:2012 |g number:2 |g pages:178-184 |g extent:7 |a Determination of rivaroxaban in human plasma samples |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0032-1301415 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.thieme-connect.de/DOI/DOI?10.1055/s-0032-1301415 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180809 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1020469730 |a Krämer, Roland |m 1020469730:Krämer, Roland |d 120000 |d 120200 |e 120000PK1020469730 |e 120200PK1020469730 |k 0/120000/ |k 1/120000/120200/ |p 4 |y j | ||
| 998 | |g 1031801979 |a Hetjens, Svetlana |m 1031801979:Hetjens, Svetlana |d 60000 |d 65400 |e 60000PH1031801979 |e 65400PH1031801979 |k 0/60000/ |k 1/60000/65400/ |p 3 | ||
| 998 | |g 1048606996 |a Erdle, Sandra |m 1048606996:Erdle, Sandra |d 60000 |d 65400 |e 60000PE1048606996 |e 65400PE1048606996 |k 0/60000/ |k 1/60000/65400/ |p 2 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |d 65400 |e 60000PH108825507 |e 65400PH108825507 |k 0/60000/ |k 1/60000/65400/ |p 1 |x j | ||
| 999 | |a KXP-PPN157841816X |e 3020498597 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title":"Determination of rivaroxaban in human plasma samples","title_sort":"Determination of rivaroxaban in human plasma samples"}],"recId":"157841816X","name":{"displayForm":["Job Harenberg, Sandra Erdle, Svetlana Marx, Roland Krämer"]},"origin":[{"dateIssuedDisp":"17. Februar 2012","dateIssuedKey":"2012"}],"person":[{"given":"Job","display":"Harenberg, Job","family":"Harenberg","role":"aut"},{"role":"aut","display":"Erdle, Sandra","given":"Sandra","family":"Erdle"},{"role":"aut","given":"Svetlana","display":"Hetjens, Svetlana","family":"Hetjens"},{"display":"Krämer, Roland","given":"Roland","family":"Krämer","role":"aut"}],"relHost":[{"language":["eng"],"disp":"Determination of rivaroxaban in human plasma samplesSeminars in thrombosis and hemostasis","recId":"342892754","pubHistory":["Nachgewiesen 1.1974,2 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Seminars in thrombosis and hemostasis","title_sort":"Seminars in thrombosis and hemostasis"}],"origin":[{"dateIssuedDisp":"1974-","publisher":"Thieme","publisherPlace":"New York, NY ; Stuttgart","dateIssuedKey":"1974"}],"note":["Gesehen am 07.11.2013"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"doi":["10.1055/s-00000077"],"issn":["1098-9064"],"zdb":["2072469-X"],"eki":["342892754"]},"part":{"extent":"7","issue":"2","text":"38(2012), 2, Seite 178-184","volume":"38","year":"2012","pages":"178-184"}}],"note":["Gesehen am 09.08.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1055/s-0032-1301415"],"eki":["157841816X"]},"physDesc":[{"extent":"7 S."}]} | ||
| SRT | |a HARENBERGJDETERMINAT1720 | ||